Business Wire

TRM Labs Acquires UK Crypto Investigations Training Company CSITech

13.6.2022 19:32:00 EEST | Business Wire | Press release

Share

Today, TRM Labs, the blockchain intelligence company, announced the acquisition of CSITech, a global leader in crypto and blockchain investigative training. CSITech adds its nearly two decades of investigative training experience to TRM’s suite of compliance tools and service offerings for crypto business, government and law enforcement agency, and financial institution clientele.

CSITech, a UK-based firm, delivers in-person and online training on blockchain and cryptocurrency investigations. CSITech is widely recognized as the leading crypto investigations training firm and has trained international law enforcement bodies at all levels on investigative techniques and best practices for investigating cryptocurrency-related crimes.

“TRM is on a mission to bring trust and safety to the crypto economy. Providing first-rate tools and training to law enforcement and compliance professionals that help safeguard this ecosystem is a core component,” said Esteban Castaño, co-founder and CEO of TRM Labs. “We’re excited about the expanded training capabilities Nick and his team of experts will allow us to offer to our global base of customers.”

CSITech’s expertise will augment and expand TRM’s existing portfolio of training services, which includes TRM Academy – an extensive library of self-serve digital courses available to all TRM customers as a complimentary resource – and several multi-day certification courses designed to advance the skills of professionals ranging compliance practitioners who are new to crypto to experienced crypto investigators.

“We’re committed to delivering the best training and certifications to our students, clients and partners in pursuit of our tireless mission to see the crypto space become a safer and more trustworthy environment for all,” said Nick Furneaux, Managing Director at CSITech.

“The pro level courses we are delivering are for those with a high existing knowledge base, who have taken a number of existing courses available and are looking to acquire the techniques and skills to take their capabilities, services offerings and careers to the next level.”

Mr. Furneaux is an internationally renowned expert of blockchain forensics and author of Investigating Cryptocurrencies: Understanding, Extracting, and Analyzing Blockchain Evidence (2018). In 18 years of operation, CSITech established itself as the preeminent crypto investigations training provider with top law enforcement agents among its alumni. Former pupils are currently leading some of the most well known cryptocurrency investigations in the sector, including cases involving hacks against exchanges, organized crime groups and sanctions evasion.

“Since 2019, TRM Labs has constantly innovated to build a blockchain investigations tool for today’s crypto ecosystem. We at CSITech are thrilled to join TRM on its mission to build a safer financial system for billions of people and expand our capability to train the next generation of leading cryptocurrency investigators,” said Furneaux. He and other CSITech personnel join TRM’s Training and Certifications team, operating in close collaboration with TRM’s Global Investigations team led by former IRS-Criminal Investigations (IRS-CI) Special Agent Chris Janczewski, who joined TRM in March 2022.

“The cryptocurrency space is evolving at tremendous pace and requires investigators and industry leaders to educate and prepare to match the industry’s scale,” said Chris Janczewski, Head of Global Investigations for TRM. “My team and I work closely with TRM’s Training and Certifications program to ensure that the course material continues to reflect the reality of the job on the ground.”

TRM’s certifications portfolio includes a range of multi-day course offerings that can be delivered virtually or in-person: TRM Crypto Fundamentals Certification (TRM-CFC), TRM Certified Crypto Compliance Specialist (TRM-CCS), TRM Certified Investigator (TRM-CI) and TRM Advanced Crypto Investigator (TRM-ACI). For more information and to enquire about booking group or individual courses, visit the TRM website here.

About TRM Labs

TRM provides blockchain intelligence to help financial institutions, cryptocurrency businesses and public agencies detect, investigate and manage crypto-related fraud and financial crime. TRM's risk management platform includes solutions for cryptocurrency anti-money laundering (AML), transaction monitoring and wallet screening, entity risk scoring including Know-Your-VASP, and transaction tracing for investigations. These tools enable a rapidly growing cohort of organizations around the world to safely embrace cryptocurrency-related transactions, products, and partnerships. TRM is based in San Francisco, CA and is hiring across engineering, product, sales, and data science. To learn more, visit www.trmlabs.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Rachel Saulpaugh
trm-labs@wachsman.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 16:30:00 EEST | Press release

FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and execution management workflow is becoming increasingly important. FlexTrade's integration with Portx builds on FlexONE's existing real-time front-office risk analytics capabilities, inclu

Xsolla Connect Returns to Brighton13.7.2026 16:22:00 EEST | Press release

Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event will build on that momentum by providing attendees with a dedicated space to connect with peers

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ

Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release

Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye